Kenvue stock (US49177J1025): Investor focus after recent results and consumer health trends

Kenvue, the consumer health group carved out of Johnson & Johnson, stays in focus after its latest quarterly update and ongoing portfolio moves. The stock attracts attention from US investors looking at branded over?the?counter and personal care demand.

Kenvue, the consumer health company spun off from Johnson & Johnson, has remained in the spotlight following its recent quarterly results and ongoing portfolio optimization, which highlight demand trends for over-the-counter medicines and personal care products, according to company filings and earnings materials published in 2024 and 2025 on its website and regulatory platforms, as reported by Kenvue website as of 03/20/2025 and by SEC filing as of 02/15/2025.

Recent updates have underlined both steady revenue contributions from heritage brands such as Tylenol, Listerine and Neutrogena and the challenges of cost inflation and currency effects on margins, with management discussing pricing actions and productivity initiatives in the latest earnings commentary, according to Kenvue quarterly results page as of 03/20/2025.

As of: 05/22/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Kenvue
• Sector/industry: Consumer health and personal care
• Headquarters/country: United States
• Core markets: North America, Europe, Asia and Latin America
• Key revenue drivers: Over-the-counter medicines, skincare, oral care and self-care brands
• Home exchange/listing venue: New York Stock Exchange (ticker: KVUE)
• Trading currency: US dollar (USD)

Kenvue: core business model

Kenvue operates a portfolio-based consumer health model anchored in well-known brands that target everyday needs in pain relief, allergy, cough and cold, skincare, sun care, baby care and oral hygiene. The company generates revenue primarily through sales to retailers, e-commerce platforms and pharmacies, with global reach in both developed and emerging markets, according to its annual report for the year ended December 29, 2024 published on February 15, 2025 on the SEC’s website, as shown by SEC filing as of 02/15/2025.

The business is organized into categories that group similar products and consumer needs, such as self care, skin health and beauty, and essential health, allowing management to allocate marketing budgets and innovation spending to areas with the strongest demand and brand equity. This structure reflects the company’s legacy under Johnson & Johnson while focusing on stand-alone priorities as an independent consumer health group, as discussed in its 2024 Form 10-K and related investor presentations summarized by Kenvue investor presentation as of 03/07/2025.

Management describes Kenvue’s strategy as combining trusted science-backed brands with extensive distribution and marketing capabilities. This emphasis on brand trust is important in consumer health categories where shoppers often rely on familiar labels for self-medication and personal care, particularly in cold and flu products, analgesics and sun protection. The company also highlights digital engagement and data-driven marketing as tools to reach consumers more directly and adapt campaigns to changing shopping behavior, as outlined in presentations to investors during 2024 and early 2025 cited by Kenvue events and presentations as of 03/10/2025.

Main revenue and product drivers for Kenvue

According to Kenvue’s Form 10-K for the fiscal year 2024, self care is a significant contributor to net sales, including brands such as Tylenol pain relief and Zyrtec for allergy management, which benefit from year-round demand and seasonal peaks, particularly in markets like the United States and Europe, as reported by SEC filing as of 02/15/2025. These products rely on broad retail distribution across pharmacies, supermarkets, mass merchandisers and online channels.

Another key pillar is skin health and beauty, where brands such as Neutrogena, Aveeno and Clean & Clear serve different consumer segments, from dermatologically inspired skincare to mass-market offerings. Performance in this category can be sensitive to shifts in consumer spending and competition from private labels and specialty skincare brands, with Kenvue highlighting innovation, dermatological partnerships and marketing campaigns as levers to support pricing and volume. The importance of this category for the company’s growth ambitions was underlined during its 2024 investor day, according to Kenvue investor presentation as of 03/07/2025.

Essential health, which includes oral care products like Listerine mouthwash, baby care and other daily-use items, provides a stream of recurring revenue supported by habitual purchase patterns. Listerine, in particular, is positioned as both a hygiene and wellness product, and the brand’s global footprint helps diversify Kenvue’s geographic exposure. The company has indicated that price increases, product mix and premium offerings have played a role in maintaining growth in this area despite cost inflation in recent years, according to commentary in its 2024 earnings materials published on March 7, 2025 and summarized by Kenvue quarterly results page as of 03/20/2025.

Conclusion

Kenvue offers US and global investors exposure to a diversified portfolio of consumer health and personal care brands with established market positions and broad distribution. Recent filings and presentations emphasize the company’s focus on driving growth through brand investment, innovation and productivity measures while managing cost pressures and competitive dynamics. The stock’s appeal for different investor profiles may depend on views about long-term demand for self-care products, the company’s ability to protect margins and how it executes as an independent consumer health player after its separation from Johnson & Johnson, as reflected in disclosures and commentary on its website and in SEC documents.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.